From the Journals

CD68/CD163 Mark Worse Outcomes in Skeletal Hodgkin Lymphoma, Study

Skeletal classic Hodgkin lymphoma shows a macrophage-rich, B-cell–poor microenvironment, with high CD68/CD163 linked to worse survival.

Share

Recent research shows skeletal classic Hodgkin lymphoma is characterized by a macrophage-rich and B-cell-poor tumor microenvironment, which correlates with worse overall survival among patients treated with a combination of chemotherapy agents. A comparison of patients with skeletal disease against those with nodal-only disease revealed distinct gene expression profiles, with higher macrophage markers like CD68 and CD163 and lower B-cell markers such as CD20. The study found that skeletal involvement significantly impacts overall survival, suggesting macrophage markers may guide treatment strategies.

Original Source(s)

CD68/CD163 Mark Worse Outcomes in Skeletal Hodgkin Lymphoma, Study

Skeletal classic Hodgkin lymphoma shows a macrophage-rich, B-cell–poor microenvironment, with high CD68/CD163 linked to worse survival.

  • by Kathryn Wighton

  • August 28, 2025

  • 3 min

Related Content

Short TTP Linked to Infective Endocarditis Risk

While shorter time to blood culture positivity was linked with infective endocarditis, it was not associated with mortality or sepsis in Streptococcus agalactiae bacteremia.

Putting a POC Troponin to the Test

Independent verification shows strong precision and concordance with lab assays across clinical thresholds.

Pathology Meets Play: The Video Game That Trains Your Diagnostic Eye

Learning to identify clues in unexpected places prepared me for real-world diagnosis at the microscope